Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $21.05, but opened at $21.8999. Chugai Pharmaceutical shares last traded at $21.0450, with a volume of 34,887 shares trading hands.

Analysts Set New Price Targets

CHGCY has been the subject of several research analyst reports. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Down 1.9%

The company has a 50-day moving average price of $21.93 and a two-hundred day moving average price of $24.84. The stock has a market capitalization of $67.51 billion, a P/E ratio of 22.29 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. Research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.